Research Analysts Offer Predictions for KNSA FY2026 Earnings

Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) – Research analysts at Wedbush dropped their FY2026 earnings estimates for shares of Kiniksa Pharmaceuticals in a research report issued on Monday, January 13th. Wedbush analyst D. Nierengarten now anticipates that the company will post earnings of $1.07 per share for the year, down from their prior estimate of $1.08. Wedbush currently has a “Outperform” rating and a $34.00 target price on the stock. The consensus estimate for Kiniksa Pharmaceuticals’ current full-year earnings is ($0.55) per share. Wedbush also issued estimates for Kiniksa Pharmaceuticals’ FY2027 earnings at $1.44 EPS.

Kiniksa Pharmaceuticals (NASDAQ:KNSA) last issued its earnings results on Tuesday, October 29th. The company reported ($0.18) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.01) by ($0.17). The business had revenue of $112.21 million during the quarter, compared to the consensus estimate of $111.51 million. Kiniksa Pharmaceuticals had a negative return on equity of 7.31% and a negative net margin of 2.36%. The company’s revenue for the quarter was up 67.4% compared to the same quarter last year. During the same quarter in the previous year, the firm posted ($0.20) earnings per share.

A number of other analysts have also commented on KNSA. Evercore ISI boosted their price target on shares of Kiniksa Pharmaceuticals from $30.00 to $35.00 and gave the company an “outperform” rating in a research note on Wednesday, October 30th. JPMorgan Chase & Co. boosted their target price on shares of Kiniksa Pharmaceuticals from $39.00 to $40.00 and gave the stock an “overweight” rating in a research report on Tuesday, November 5th. Five analysts have rated the stock with a buy rating, According to MarketBeat.com, Kiniksa Pharmaceuticals presently has a consensus rating of “Buy” and a consensus target price of $36.60.

Kiniksa Pharmaceuticals Price Performance

KNSA stock opened at $18.82 on Wednesday. The company’s 50-day moving average is $20.94 and its 200-day moving average is $23.27. The stock has a market capitalization of $1.36 billion, a PE ratio of -134.42 and a beta of 0.29. Kiniksa Pharmaceuticals has a 1 year low of $16.56 and a 1 year high of $28.15.

Hedge Funds Weigh In On Kiniksa Pharmaceuticals

Several institutional investors and hedge funds have recently made changes to their positions in KNSA. Wellington Management Group LLP purchased a new stake in Kiniksa Pharmaceuticals during the 3rd quarter valued at about $1,192,000. Dimensional Fund Advisors LP boosted its stake in shares of Kiniksa Pharmaceuticals by 31.2% during the second quarter. Dimensional Fund Advisors LP now owns 664,040 shares of the company’s stock valued at $12,398,000 after purchasing an additional 157,741 shares during the period. Segall Bryant & Hamill LLC bought a new position in shares of Kiniksa Pharmaceuticals in the third quarter worth approximately $675,000. Parkman Healthcare Partners LLC grew its holdings in shares of Kiniksa Pharmaceuticals by 16.7% in the third quarter. Parkman Healthcare Partners LLC now owns 755,244 shares of the company’s stock worth $18,874,000 after purchasing an additional 108,102 shares during the last quarter. Finally, Millennium Management LLC increased its stake in shares of Kiniksa Pharmaceuticals by 159.8% in the second quarter. Millennium Management LLC now owns 621,948 shares of the company’s stock worth $11,612,000 after buying an additional 382,539 shares during the period. Institutional investors own 53.95% of the company’s stock.

Insiders Place Their Bets

In other news, COO Eben Tessari sold 14,000 shares of the company’s stock in a transaction on Monday, January 13th. The shares were sold at an average price of $18.24, for a total value of $255,360.00. Following the transaction, the chief operating officer now owns 88,975 shares of the company’s stock, valued at approximately $1,622,904. This represents a 13.60 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, CFO Mark Ragosa sold 8,969 shares of the company’s stock in a transaction dated Tuesday, December 3rd. The stock was sold at an average price of $21.45, for a total value of $192,385.05. Following the completion of the transaction, the chief financial officer now owns 22,958 shares in the company, valued at $492,449.10. This represents a 28.09 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 24,092 shares of company stock worth $471,609 in the last quarter. 54.57% of the stock is owned by company insiders.

About Kiniksa Pharmaceuticals

Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, that is in Phase 2b clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response.